Existing infrastructures of partner laboratories and clinical leading centres in European countries will be harmonised and reinforced into a task force to achieve clinical (phenotypes), genetic material and genotype repository from anklylosing sodalities (AS) and the other spondylarthropathies (SPA), thanks to the access to up to 00 affected families. After diagnostic ascertaining, informative families will be recruited. All needed clinical data (including severity assessment, co morbidities) from AS patients and unaffected individuals will be collected. DNA, cells, sera and transformed cell lines (EBV) will be stored in a central bank for researcher use. Only such a large repository will give enough power to monogenetic, candidate gene, genome wide screen and fine gene mapping studies to successfully identify new AS susceptibility and severity genes, allowing the development of new therapeutic (gene therapy) and preventive approaches.
Funding SchemeCSC - Cost-sharing contracts
LS2 9NZ Leeds